Latest News

AAAAI 2026 highlights STMC-103H live biotherapeutic, showing reduced atopic disease risk in at-risk infants—potential early microbiome intervention for AD and food allergy.

A practical look at redesigning tasks and integrating AI to improve efficiency and patient outcomes

Add beans and legumes to your diet for better health: boost fiber and key nutrition, improve blood sugar, heart health, digestion, and weight control.

At 2026 ASCO GU, emerging targets are reshaping how mCRPC is treated.

Remibrutinib, an oral Bruton tyrosine kinase inhibitor for chronic spontaneous urticaria (CSU), delivers itch and hive relief within 12 hours and sustains improvements through week 1.

Data presented at AAAAI 2026 show tapinarof cream improves sleep for children as young as 2 years with atopic dermatitis, easing nighttime disruption.

Sheryl L. Chow, PharmD, outlines the pharmacist's evolving role in cardiovascular prevention, heart failure management, and medication adherence during American Heart Month and beyond.

Data from ASCO GU show the benefit of the enfortumab vedotin combination in muscle-invasive bladder cancer, challenging cisplatin neoadjuvant chemotherapy.

Artificial intelligence helps hematology teams and pharmacists distinguish prefibrotic myelofibrosis from essential thrombocythemia, improving myeloproliferative neoplasm diagnosis accuracy and oncology care.

A large cohort study found that urate-lowering therapy was associated with a reduction in risk for composite kidney outcomes in patients with stage 3 or higher chronic kidney disease (CKD) and hyperuricemia.

Explore PREVENT Risk Equations reshaping hypertension care, HFpEF therapy, and CKD-related hyperkalemia.

Capivasertib plus abiraterone improves survival in PTEN-deficient hormone-sensitive prostate cancer.

PEACE-3 trial data presented at ASCO GU show survival benefits with enzalutamide combination.

Carfilzomib may boost BCMA CAR T-cell therapy after relapse in multiple myeloma, guiding oncology pharmacists on safer immunotherapy sequencing.

The approval is supported by findings from the phase 1 Beamion LUNG-1 clinical trial.

Learn how COVID-19 drives heart and vascular risks, why vaccines and antivirals help, and how pharmacists manage dangerous drug interactions.

Orforglipron, an oral GLP-1 medication, demonstrated superior weight loss and blood glucose control compared with oral semaglutide in patients with type 2 diabetes (T2D).

Awareness of the nonlinear response helps ensure patients are treated with the least intensive regimen that achieves meaningful control while minimizing harm and improving long-term therapeutic success.

The oral solution improves central diabetes insipidus dosing precision, helping pharmacy teams tailor therapy, counsel patients, and monitor hyponatremia.

Collaborative practice agreements expand pharmacists’ clinical authority and patient access.

Flexibility, priorities, and structure are just as important as your account balance.